What is the 13F Pro Quality Score for WST?

13F Pro ranks WEST PHARMACEUTICAL SERVICES INC (WST) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View WST's current score at https://13fpro.ai/research/WST (free sign-up required for the full ranking).

Where does 13F Pro source WST data?

All WEST PHARMACEUTICAL SERVICES INC fundamentals and ownership data come directly from SEC EDGAR. WEST PHARMACEUTICAL SERVICES INC files with the SEC under CIK 105770. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is WST in?

WEST PHARMACEUTICAL SERVICES INC (WST) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives WST's revenue?

Per WEST PHARMACEUTICAL SERVICES INC's latest 10-Q filed with the SEC on 2026-04-23, the biggest revenue drivers are: Proprietary Products ($694.3M, +23.3% YoY); West Vantage ($150.6M, +11.6% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/WST.

What are WST's largest expenses?

WEST PHARMACEUTICAL SERVICES INC's latest 10-Q reports these as the largest expense items: Selling, general and administrative expenses ($99.5M, +13.1% YoY); Research and development ($15.8M, -3.1% YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is WST research updated on 13F Pro?

WST's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

WEST PHARMACEUTICAL SERVICES INC(WST)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSE

Institutional-grade research for retail investors

SEC EDGAR: CIK 105770 WST stock profile & AI dashboard →

13F Pro Quality Score

66.8/100

Rank #500 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

45.0/100

Profitability

75.2/100

Balance Sheet

89.5/100

Earnings Quality

30.3/100

Free Cash Flow

65.5/100

Institutional Flow

84.8/100

Revenue Scale

70.4/100

Dilution Risk

64.2/100

WST Stock Analysis & AI Quality Score

AI stock analysis and institutional research for WEST PHARMACEUTICAL SERVICES INC (WST), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores WST at 66.8/100 on a 32-signal composite quality model, placing it at rank #500 of 2,879 stocks — the top 25% of the AI-ranked universe. WST scores in the top quartile across balance sheet strength (89.5), institutional flow (84.8), profitability (75.2). Areas of concern include earnings quality (30.3), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), WEST PHARMACEUTICAL SERVICES INC reports quarterly revenue of $844.9M, net income of $138.8M, an operating margin of 21.0%. Top institutional holders of WST by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. WST trades on the NYSE exchange and files with the SEC under CIK 105770. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate WST daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for WEST PHARMACEUTICAL SERVICES INC directly from SEC EDGAR. WEST PHARMACEUTICAL SERVICES INC's 13F Pro composite quality score has ranged between 8 and 76 since 2021, currently 66.8 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about WEST PHARMACEUTICAL SERVICES INC

Quirks, history, and lore behind WST — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. industrial/healthcare company · mid-cap · listed on the NYSE · headquartered in Pennsylvania.
2
The Numbers
Annual revenue in the range of $3 billion, with operating margins that would make a pharma CFO nod approvingly — this is a high-precision, high-margin niche business.
3
The History
Founded in 1923, it spent a century quietly becoming the world's go-to supplier of containment and delivery components for injectable drugs — an unglamorous throne nobody else really wanted.
4
The Secret
Every time a vaccine or biologic gets filled into a vial, there's a good chance this company made the rubber stopper or plastic closure sealing it shut.
5
The Lore
COVID-19 vaccine rollouts sent its stock soaring as demand for drug-packaging components exploded — billions of doses means billions of stoppers, seals, and delivery systems.
6
The Giveaway
Its name sounds like a cowboy state meets a drugstore, and its little rubber stoppers sit on top of nearly every injectable medication on the planet.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving WST's Business? Latest 10-Q Breakdown

AI-extracted from WEST PHARMACEUTICAL SERVICES INC's 10-Q filed 2026-04-23 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

West Pharmaceutical Q1 2026 net sales reached $844.9M (+21.0% YoY), with organic growth of 15.3%, driven by strong demand for high-value components and self-injection devices.

Biggest Revenue Drivers

Total revenue: $844.9M+21.0% YoY

Proprietary Products$694.3M+23.3% YoY

Increased customer demand for Westar®, NovaPure® and FluroTec® products, as well as self-injection device platforms; favorable foreign currency translation of $32.8M.

West Vantage$150.6M+11.6% YoY

Increase in sales of self-injection devices for obesity and diabetes; favorable foreign currency translation of $7.2M.

Largest Expense Items

Selling, general and administrative expenses$99.5M+13.1% YoY

Increased expense related to stock-based compensation and increased salary and wages.

Research and development$15.8M-3.1% YoY

Focused on primary injectables in elastomeric components and drug containment systems.

Margins: Consolidated gross profit margin expanded 1.9 percentage points to 35.1% YoY, driven by Proprietary Products margin expansion of 2.0 points from increased customer demand and sales price increases, partially offset by West Vantage margin contraction of 0.6 points due to increased production costs. Operating profit margin improved to 21.0% from 15.3% YoY.

Watch Items from the Filing

SmartDose® 3.5mL On-Body Delivery System sale to AbbVie for ~$112.5M expected to close mid-2026; $58.2M in assets classified as held for sale; restructuring charges expected $15M-$20M.
Two restructuring plans underway: January 2025 plan expecting $30M-$32M in total charges with $35M-$40M annualized savings; December 2025 SmartDose® sale plan expecting $15M-$20M charges with $15M-$20M annualized savings.
Securities class action filed May 5, 2025 alleging violations of Securities Exchange Act related to public statements and officer stock transactions; case in early stages with motion to dismiss pending; unable to estimate losses.
Tariff and trade restrictions imposed by U.S. government beginning 2025; company believes impact will not be material to 2026 results; petro-chemical cost inflationary pressures anticipated but expected not to materially impact operations.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$844.9M

Net Income

Q1 2026

$138.8M

Free Cash Flow

Q1 2026

$47.2M

Operating Margin

Q1 2026

21.0%

D/E Ratio

Q1 2026

0.07

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+6.3% YoY

$3.07BFY 2025

FY21 $2.83BFY23 $2.95BFY24 $2.89BFY25 $3.07B

Net Income

+0.2% YoY

$493.7MFY 2025

FY21 $661.8MFY23 $593.4MFY24 $492.7MFY25 $493.7M

Operating Income

+2.6% YoY

$584.9MFY 2025

FY21 $752.3MFY23 $676.0MFY24 $569.9MFY25 $584.9M

EPS (Diluted)

+1.5% YoY

$6.79FY 2025

FY21 $8.67FY23 $7.88FY24 $6.69FY25 $6.79

Total Assets

+17.2% YoY

$4.27BFY 2025

FY21 $3.31BFY23 $3.83BFY24 $3.64BFY25 $4.27B

Total Debt

+0.1% YoY

$202.8MFY 2025

FY21 $341.4MFY23 $340.8MFY24 $202.6MFY25 $202.8M

Op. Cash Flow

+15.5% YoY

$754.8MFY 2025

FY21 $584.0MFY23 $776.5MFY24 $653.4MFY25 $754.8M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	$3.07B +6.3%	$2.89B -1.9%	$2.95B +4.2%	$2.83B +31.9%	$2.15B +16.7%	$1.84B
Net Income	$493.7M +0.2%	$492.7M -17.0%	$593.4M -10.3%	$661.8M +91.2%	$346.2M +43.2%	$241.7M
Operating Income	$584.9M +2.6%	$569.9M -15.7%	$676.0M -10.1%	$752.3M +84.9%	$406.9M +37.2%	$296.6M
EPS (Diluted)	$6.79 +1.5%	$6.69 -15.1%	$7.88 -9.1%	$8.67 +89.7%	$4.57 +42.4%	$3.21
Total Assets	$4.27B +17.2%	$3.64B -4.9%	$3.83B +15.6%	$3.31B +18.6%	$2.79B +19.3%	$2.34B
Total Debt	$202.8M +0.1%	$202.6M -40.6%	$340.8M -0.2%	$341.4M +31.4%	$259.8M -0.8%	$261.9M
Operating Cash Flow	$754.8M +15.5%	$653.4M -15.9%	$776.5M +33.0%	$584.0M +23.6%	$472.5M +28.7%	$367.2M

AI Insight: WST Ratio Trends

West Pharmaceutical shows strong profitability recovery with operating margin rebounding to 21.0% in Q1 2026 after Q1 2025 dip.

• Operating margin recovered from 15.3% trough in Q1 2025 to 21.0% in Q1 2026.

• ROIC strengthened to 22.2% in Q1 2026, highest level since Q4 2024.

• Debt-to-equity ratio remains consistently low at 0.07 in latest quarter.

⚠ ROE declined to 16.6% in Q4 2025 before recovering to 18.6% in Q1 2026.

⚠ Q1 2025 showed significant margin compression across all profitability metrics before recovery.

Get alerted when WST's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for WEST PHARMACEUTICAL SERVICES INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of WST

BlackRock, Inc.
$1.7B6,836,714 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.2B4,683,286 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.0B4,094,009 sh
STATE STREET CORP
$825.6M3,293,778 sh
Artisan Partners Limited Partnership
$666.2M2,657,893 sh
Bank of New York Mellon Corp
$618.0M2,465,858 sh
GENERATION INVESTMENT MANAGEMENT LLP
$562.4M2,243,976 sh
GEODE CAPITAL MANAGEMENT, LLC
$477.5M1,912,455 sh
MORGAN STANLEY
$365.5M1,458,282 sh
BROWN ADVISORY INC
$336.1M1,340,877 sh

Fund	Value	Shares
BlackRock, Inc.	$1.7B	6,836,714
VANGUARD CAPITAL MANAGEMENT LLC	$1.2B	4,683,286
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.0B	4,094,009
STATE STREET CORP	$825.6M	3,293,778
Artisan Partners Limited Partnership	$666.2M	2,657,893
Bank of New York Mellon Corp	$618.0M	2,465,858
GENERATION INVESTMENT MANAGEMENT LLP	$562.4M	2,243,976
GEODE CAPITAL MANAGEMENT, LLC	$477.5M	1,912,455
MORGAN STANLEY	$365.5M	1,458,282
BROWN ADVISORY INC	$336.1M	1,340,877

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put WST on your watchlist

Track score changes the day WEST PHARMACEUTICAL SERVICES INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is WST a good stock to buy?

13F Pro's AI-powered analysis of WEST PHARMACEUTICAL SERVICES INC (WST) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for WST are available on the WST stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own WST?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling WST. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of WEST PHARMACEUTICAL SERVICES INC's investment landscape.